2seventy Bio sees Q3 Abecma U.S. revenue growth ~ 30% vs. Q2

2seventy (TSVT) is pleased to report continued positive momentum in Abecma’s expected return to growth in the earlier line setting following the FDA’s approval in April 2024. The company expects third quarter Abecma U.S. revenue growth of approximately 30% from second quarter revenue of $54M. Demand, as measured by new patients undergoing apheresis in the third quarter, is also expected to reflect double-digit growth when compared to the second quarter of 2024. The company remains committed to driving the continued success of Abecma in 2024 and beyond. 2seventy bio and Bristol Myers (BMY) share equally in all profits and losses related to development, manufacturing, and commercialization of Abecma in the U.S.